A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.

[1]  Sadashiv Santosh,et al.  Anaphylaxis with elevated serum tryptase after administration of intravenous ferumoxytol , 2010, NDT plus.

[2]  R. Pazdur,et al.  FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease , 2010, American journal of hematology.

[3]  D. Coyne,et al.  Anemia management in chronic kidney disease: Intravenous iron steps forward , 2010, American journal of hematology.

[4]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[5]  I. Macdougall.  Evolution of iv iron compounds over the last century. , 2009, Journal of renal care.

[6]  J. García-Erce,et al.  Intravenous iron in inflammatory bowel disease. , 2009, World journal of gastroenterology.

[7]  A. Kausz,et al.  Physicochemical properties of ferumoxytol, a new intravenous iron preparation , 2009, European journal of clinical investigation.

[8]  Maya K. Rao.  Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care , 2009 .

[9]  M. Auerbach,et al.  Intravenous iron in oncology. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

[10]  J. García-Erce,et al.  Efficacy and safety of intravenous iron therapy as an alternative/adjunct to allogeneic blood transfusion , 2008, Vox sanguinis.

[11]  R. Neubert,et al.  CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off‐capillary and on‐capillary complexation with EDTA , 2007, Electrophoresis.

[12]  I. Macdougall,et al.  OPTA-therapy with iron and erythropoiesis-stimulating agents in chronic kidney disease , 2007 .

[13]  H. Cohen,et al.  Serious hazards of transfusion: a decade of hemovigilance in the UK. , 2006, Transfusion medicine reviews.

[14]  J. García-Erce,et al.  Intravenous Iron in Cardiac Surgery , 2006 .

[15]  K. Ljungström.  Pretreatment with dextran 1 makes dextran 40 therapy safer. , 2006, Journal of Vascular Surgery.

[16]  G. Chertow,et al.  Update on adverse drug events associated with parenteral iron. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  F. Lázaro,et al.  Magnetostructural study of iron sucrose , 2005 .

[18]  B. Danielson.  Structure, chemistry, and pharmacokinetics of intravenous iron agents. , 2004, Journal of the American Society of Nephrology : JASN.

[19]  G. Aronoff.  Safety of intravenous iron in clinical practice: implications for anemia management protocols. , 2004, Journal of the American Society of Nephrology : JASN.

[20]  A. Ulman,et al.  Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. , 2004, Journal of inorganic biochemistry.

[21]  R. Zager,et al.  Parenteral iron nephrotoxicity: Potential mechanisms and consequences1 , 2004 .

[22]  G. Chertow,et al.  On the relative safety of parenteral iron formulations. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[23]  G. Rodgers,et al.  Parenteral iron therapy options , 2004, American journal of hematology.

[24]  R. Zager,et al.  Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[25]  G. Chertow,et al.  Suspected iron dextran-related adverse drug events in hemodialysis patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  P. Weidler,et al.  Physical and Chemical Characterization of Therapeutic Iron Containing Materials: A Study of Several Superparamagnetic Drug Formulations with the β-FeOOH or Ferrihydrite Structure , 2001 .

[27]  E. Bergstralh,et al.  Adverse Events in Chronic Hemodialysis Patients Receiving Intravenous Iron Dextran – A Comparison of Two Products , 2000, American Journal of Nephrology.

[28]  S. Fishbane,et al.  The Comparative Safety of Intravenous Iron Dextran, Iron Saccharate, and Sodium Ferric Gluconate , 2000, Seminars in dialysis.

[29]  A. Huch,et al.  Effectiveness of recombinant erythropoietin and iron sucrose vs. iron therapy only, in patients with postpartum anaemia and blunted erythropoiesis , 2000, European journal of clinical investigation.

[30]  Jens Ø. Duus,et al.  A Conformational Study of Hydroxymethyl Groups in Carbohydrates Investigated by 1H NMR Spectroscopy , 1994 .

[31]  K. Ljungström,et al.  Safety of dextran in relation to other colloids--ten years experience with hapten inhibition. , 1993, Infusionstherapie und Transfusionsmedizin.

[32]  P. Geisser,et al.  Structure/histotoxicity relationship of parenteral iron preparations. , 1992, Arzneimittel-Forschung.

[33]  I. Panel.  Revised recommendations for the measurements of the serum iron in human blood , 1990, British journal of haematology.

[34]  C. R. Gibbs.  Characterization and application of FerroZine iron reagent as a ferrous iron indicator , 1976 .

[35]  W. Richter.  Minimal molecular size of dextran required to elicit heterologous passive cutaneous anaphylaxis in guinea pigs. , 1972, International archives of allergy and applied immunology.

[36]  H. Yee,et al.  An autoanalyzer procedure for serum iron and total iron-binding capacity, with use of ferrozine. , 1971, Clinical chemistry.

[37]  P Carter,et al.  Spectrophotometric determination of serum iron at the submicrogram level with a new reagent (ferrozine). , 1971, Analytical biochemistry.

[38]  E. J. Coulson,et al.  Some observations on the immunochemistry of dextrans. , 1961, Journal of immunology.

[39]  A. D. Meere,et al.  Evaluation of the Physical Stability of Freeze-Dried Sucrose-Containing Formulations by Differential Scanning Calorimetry , 2004, Pharmaceutical Research.

[40]  G. Glöckner.  Polymer characterization by liquid chromatography , 1987 .

[41]  A. W. Richter.  Immune Complex Anaphylaxis Induced by Dextran and Its Elimination by Hapten Inhibition , 1986 .

[42]  W. Richter,et al.  Prevention of dextran-induced anaphylactic reactions by hapten inhibition. III. A Scandinavian multicenter study on the effects of 20 ml dextran 1, 15%, administered before dextran 70 or dextran 40. , 1983, Acta chirurgica Scandinavica.

[43]  K. Messmer,et al.  Incidence, pathomechanism and prevention of dextran-induced anaphylactoid / anaphylactic reactions in man. , 1980, Developments in biological standardization.

[44]  W. Richter.  Built-in hapten inhibition of anaphylaxis by the low molecular weight subfractions of a B 512 dextran fraction of MW 3,400. , 1973, International archives of allergy and applied immunology.

[45]  W. Richter.  Hapten inhibition of passive antidextran dextran anaphylaxis in guinea pigs. Role of molecular size in anaphylactogenicity and precipitability of dextran fractions. , 1971, International archives of allergy and applied immunology.